GlobeNewswire by notified

Ress Life Investments A/S publishes notice for Annual General Meeting

Share

Ress Life Investments A/S
Nybrogade 12
1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com

To: Nasdaq Copenhagen
Date: 28 March 2023

Corporate Announcement 11/2023

Ress Life Investments A/S publishes notice for Annual General Meeting

TO THE SHAREHOLDERS OF RESS LIFE INVESTMENTS A/S

In accordance with Article 9.8 of the Articles of Association, notice is hereby given of the Annual General Meeting of Ress Life Investments A/S (the "Company") which will take place on Wednesday 19 April 2023 at 10.00 a.m. at Nybrogade 12, 1203 Copenhagen K, Denmark.

Shareholders in the Company are invited to participate.

Agenda for the Annual General Meeting:

1)     Adoption of the annual report
2)     Appropriation of profit or loss as recorded in the adopted annual report
3)     Election of members of the Board of Directors
4)     Approval of the Remuneration Report
5)     Approval of remuneration for the Board of Directors for the financial year 2023
6)     Authorisation to the board of directors to purchase own shares
7)     Authorisation to the board of directors to increase the share capital
8)     Appointment of auditor
9)     Any other business


COMPLETE PROPOSALS

Re. item 1

The Board of Directors proposes that the annual report be adopted.

Re. item 2

The Board of Directors proposes that the profit as recorded in the annual report as adopted by the general meeting should be distributed in accordance with the annual report.

Re. item 3

The Board of Directors proposes that Søren Andersen, Jeppe Buskov, Ketil Poul Petersen and Anne Buchardt be re-elected to the Board of Directors.

MrSøren Andersen has been a member of the Board of Directors of the Company since August 2018. Mr Andersen is the managing director of S.A. Consulting ApS, FPension A/S, NHMSA ApS and Specialist Sevices ApS and appointed actuary of ISP Pension. Mr Andersen currently is a board member of FPension A/S.

MrJeppeBuskov has been a member of the Board of Directors of the Company since February 2014. Mr Buskov currently holds the position as chairman of the board of directors of Kromann Reumert, Advokatfirmaet Kromann Reumert International A/S, KR 647 A/S, KR 649 A/S and KR 650 P/S.

MrKetilPoul Petersen has been a member of the Board of Directors of the Company since August 2018. Mr Petersen is a member of the Board of Directors of St. Petri Capital A/S, Dannebrog Invest Fondsmælgerselskab A/S, Dannebrog Invest Holding ApS, DFS Real Estate A/S and DFS Holding A/S and the managing director of Verismo ApS.

Mrs Anne Buchardt has been a member of the Board of Directors of the Company since January 2020. Mrs Buchardt is a member of the Board of Directors of PKA+ Pension Forsikringsselskab A/S, Pensionskassen for Sygeplejersker og Lægesekretærer (PKA), Sygeplejerskernes og Lægesekretærernes Ejendomsaktieselskab and Ejendomsaktieselskabet Dronningegården and managing director of Bølgebrus Holding ApS. Mrs Buchardt holds a M.Sc. in Economics (cand. polit) from University of Copenhagen.

Re. item 4

The Board of Directors proposes that the Remuneration Report attached to this notice be approved.

Re. item 5

The Board of Directors proposes the following remuneration for the Board of Directors for the financial year 2023:

  • Ordinary members will receive a basic remuneration of DKK 90,000
  • The chairman will receive a basic remuneration of DKK 215,000

Re. item 6

The authorization to purchase own shares in Article 6.1 of the Articles of Association has expired. Therefore, the Board of Directors requests the Annual General Meeting to authorize that, in the period up to and including 18 April 2028, the Company may acquire own shares with a total nominal value of up to 50 % of the Company's share capital. The consideration for the shares must not deviate from the price, including cost deduction, which can be calculated according to Article 5.5 and 5.6 of the Articles of Association.

Accordingly, the Board of Directors propose that the current Article 6.1 of the Articles of Association be replaced with a new authorization with the following wording:

"For a period until and including 18 April 2028 the Board of Directors is authorized to acquire, on behalf of the Company, own shares of up to 50% of the Company’s share capital. The consideration for the shares must not deviate from the price, including cost deduction, which can be calculated according to Article 5.5 and 5.6."

The proposed wording of the new Article 6.1 will in Danish read as follows:

"Bestyrelsen er bemyndiget til i perioden frem til og med den 18. april 2028 på selskabets vegne at erhverve egne aktier på indtil 50 % af selskabets aktiekapital. Vederlaget for aktierne må ikke afvige fra den kursværdi med omkostningsfradrag, der kan opgøres i henhold til punkt 5.5 og 5.6."

Re. item 7

The authorization to the Board of Directors in Article 4.8 to increase the Company's share capital will expire on 27 August 2023. The Board of Directors therefore proposes that the Board of Directors be granted a new authorization for the next five years and that the existing authorization in Article 4.8 shall terminate effective as of the general meeting.

Accordingly, the Board of Directors propose that the current Article 4.8 of the Articles of Association be replaced with a new authorization with the following wording:

"The Board of Directors is authorized to increase the share capital of the Company by issue of new shares in one or several issuances without pre-emption right for existing shareholders with a total nominal value of up to EUR 500,000,000. The shares of the capital increase must be negotiable instruments and rank equally with the existing share capital. No transferability restrictions or redemption obligations shall apply to the new shares.The shares must be registered in the name of the holder in the Company's register of shareholders. In connection with the registration the shareholder must provide an email address to which notices to the shareholders can be sent, cf. Articles 4.1 and 15. The capital increase may take place at a price which corresponds to the most recent net asset value calculation per share or higher. The authorization is valid in the period until (and including) 18 April 2028."

The proposed wording of the new Article 4.8 will in Danish read as follows:

"Bestyrelsen er bemyndiget til at forhøje aktiekapitalen ved udstedelse af nye aktier i én eller flere udstedelser uden fortegningsret for selskabets bestående aktionærer med en samlet nominel værdi på op til EUR 500.000.000. Aktierne i kapitalforhøjelsen skal være omsætningspapirer og ligestillet med den bestående aktiekapital. Der skal ikke gælde omsættelighedsbegrænsninger eller bestemmelser om indløsning. Aktierne skal være navneaktier samt noteres på navn i selskabets ejerbog. I forbindelse med navnenoteringen skal aktionæren oplyse en e-mail adresse, hvortil meddelelser til aktionæren kan sendes, jf. punkt 4.1 og 15. Kapitalforhøjelsen kan ske til en kurs, der svarer til den senest beregnede indre værdi eller højere. Bemyndigelsen gælder i perioden frem til og med den 18. april 2028."

As a consequence of the adoption of the new Article 4.8, the existing Article 4.9 must be deleted and the Board of Directors accordingly propose such amendment as an integral part of this agenda item no.7

Re. item 8

The Board of Directors proposes that Deloitte Statsautoriseret Revisionspartnerselskab should be re-elected as auditor. The Board of Directors has not been influenced by any third party and has not been bound by any third-party agreement, restricting the general meeting's choice of auditor to certain auditors or audit firms.

REGISTRATION, ADMISSION, PROXY AND POSTAL VOTE

Registration date

A shareholder’s right to participate in the general meeting and the number of votes, which the shareholder is entitled to cast, is determined in accordance with the number of shares held by such shareholder on 12 April 2023 (the registration date). The shares held by each shareholder are determined at the registration date on the basis of the shareholdings registered in the share register in accordance with any notices on shareholding received, but not yet registered, by the Company in the share register.

Deadline for notice of attendance

A shareholder or its proxy wishing to attend the general meeting must give notice of their participation to the Company no later than 14 April 2023, see Article 11.5 of the Articles of Association. Similarly, the shareholders’ advisor or the shareholders’ proxy’s advisor must give notice of their participation to the Company no later than 14 April 2023. Notice of participation may be given to the Company using the form attached as Appendix 1, which shall be sent, duly completed and signed, to Ress Life Investments A/S, Nybrogade 12, 1203 Copenhagen K, Denmark by letter or by email to RessLifeGroup@citco.com for receipt no later than 14April 2023, 23:59 p.m.

Proxy

If you are prevented from attending the general meeting, you may appoint a proxy, e.g. the Board of Directors, to cast the votes carried by your shares. If you wish to appoint a proxy, please return the instrument of proxy form attached as Appendix 2, duly signed and dated, to Ress Life Investments A/S, Nybrogade 12, 1203 Copenhagen K, Denmark by letter or by email to RessLifeGroup@citco.com for receipt no later than 14April 2023, 23:59 p.m.

Postal vote

You may also submit your votes by post before the date of the meeting. If you wish to vote by post, please fill in and return the postal vote form attached as Appendix 2, duly signed and dated, to Ress Life Investments A/S, Nybrogade 12, 1203 Copenhagen K, Denmark by letter or by email to RessLifeGroup@citco.com for receipt no later than 18April 2023, 17:00 p.m.

SHARE CAPITAL AND VOTING RIGHTS

The Company's share capital is EUR 81,434,500 divided into shares of EUR 500, cf. Article 3.1 of the Company's Articles of Association. Pursuant to Article 11.1, each share of EUR 500 carries one (1) vote:

Number of shares:162,869
Number of votes:162,869

AGENDA ETC.

The agenda and the Annual Report for the period 1 October 2022 – 31 December 2022 will be available for inspection by the shareholders on all business days and within normal business hours at the office of the Company at Nybrogade 12, 1203 Copenhagen K, Denmark no later than 3 weeks before the general meeting.

The         following         information         will         be         made         available         at         the         Company’s         website
(http://resslifeinvestments.com/) not later than 3 weeks before the meeting:

  1. Notice convening the meeting.
  2. The total number of shares and voting rights as at the date of the notice.
  3. The documents to be submitted to the general meeting.
  4. The agenda and the full text of the proposals.
  5. The forms to be used for voting by proxy and by post, if relevant

RIGHT TO INQUIRE

At the general meeting, the management will answer questions from the shareholders on matters of relevance to the assessment of the Annual Report for the period 1 October 2022 – 31 December 2022, the Company’s position, and other questions to be addressed by the meeting.

Questions related to this announcement can be made to the Company’s CEO Michael Hovard Ekmann, email: michael.hovard.ekmann@resslifeinvestments.com or to the Company’s AIF-manager, Resscapital AB, Gustaf Hagerud email: gustaf.hagerud@resscapital.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release

Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en

Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding

STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil

Interim Report - January-March 202426.4.2024 08:00:00 CEST | Press release

STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company OssDsign reported positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst

Solvay publishes notice of 2024 Annual General Meeting26.4.2024 08:00:00 CEST | Press release

Brussels, April 26, 2024, 8:00am CEST - regulated information Solvay today published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May 28, 2024 at the Event Lounge Conference Center, Boulevard Général Wahis 16/F, 1030 Brussels, at 10.30 am CEST. All documents relating to this meeting are now available on www.solvay.com. Shareholders will be asked to vote on a number of resolutions, among others: the approval of the financial statements for the financial year 2023; the approval of a total gross dividend of €2.43 per share; the approval of the revised directors’ remuneration; the renewal of the mandate, for a four-year period, of Ms Aude Thibaut de Maisières, as Director of the company; the appointment of EY regarding the assurance of sustainability information imposed by the EU Directive on sustainability reporting (Corporate Sustainability Reporting Directive); the approval of the change of control provision relating to the issuance of eur

Yara reports increased deliveries, lower prices and reduced GHG emission intensity in 1Q26.4.2024 08:00:00 CEST | Press release

First-quarter EBITDA1 was USD 435 million compared to USD 487 million in first quarter 2023. Net income was USD 16 million (USD 0.07 per share) compared with USD 105 (USD 0.41 per share) a year earlier. First-quarter 2024 highlights: EBITDA1 down 11% from 1Q23 mainly due to lower pricesTotal deliveries up 12% with European deliveries up 37% from 1Q23Reduced GHG emission intensity with implementation of key projectsHealthy demand growth and limited capacity additions indicate tightening supply-demand balance longer term “This quarter's results are down from same quarter last year as increased deliveries are offset by lower prices. Meanwhile, I am pleased to see that our efforts to decarbonize is yielding results. This is crucial to future-proof our business and be able to meet growing demand for low-carbon solutions”, said Svein Tore Holsether, President and Chief Executive Officer. Despite strong urea supply in 2023, prices are generally demand-driven with positive production margins f

HiddenA line styled icon from Orion Icon Library.Eye